Last reviewed · How we verify

Kineret — Competitive Intelligence Brief

Kineret (ANAKINRA) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interleukin-1 Receptor Antagonist [EPC]. Area: Immunology.

marketed Interleukin-1 Receptor Antagonist [EPC] Interleukin-1 receptor, type I Immunology Recombinant protein Live · refreshed every 30 min

Target snapshot

Kineret (ANAKINRA) — Biovitrum Ab. Kineret blocks the action of interleukin-1, a protein that promotes inflammation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Kineret TARGET ANAKINRA Biovitrum Ab marketed Interleukin-1 Receptor Antagonist [EPC] Interleukin-1 receptor, type I 2001-01-01
Anakinra Kineret Biovitrum Ab marketed Interleukin-1 Receptor Antagonist Interleukin-1 receptor, type I 2001-01-01
Kineret® (Anakinra) Kineret® (Anakinra) Amgen marketed Interleukin-1 receptor antagonist IL-1 receptor type I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interleukin-1 Receptor Antagonist [EPC] class)

  1. Biovitrum Ab · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Kineret — Competitive Intelligence Brief. https://druglandscape.com/ci/anakinra. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: